Experimental drug targets rare thymus cancers after chemotherapy fails

NCT ID NCT04417660

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This phase II trial tests bintrafusp alfa (M7824) in 9 adults with thymoma or thymic carcinoma that returned after platinum-based chemotherapy. Participants receive the drug intravenously every two weeks until their disease worsens or side effects become intolerable. The study aims to see if the drug can shrink tumors and how safe it is.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bintrafusp alfa (M7824)
What this could lead to: If it works, this could provide a new treatment option for people with thymoma or thymic carcinoma that has returned after standard chemotherapy.
What could go wrong: This is a small, early-phase trial with only 9 participants, so results may not apply to everyone. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT THYMOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thymic carcinoma thymic epithelial neoplasm thymoma thymus cancer Thymus Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT THYMOMA THYMIC CANCER THYMIC EPITHELIAL TUMOR

Contacts and locations

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.